Robert holds a BA from the University of Massachusetts Amherst.

Robert has worked in biopharmaceuticals and the investment sector since the early 1990s. After working with Shire PLC as Director of Business Development for Europe and Asia, in 2000 he was a founder member of Thalassa Capital Management, San Francisco responsible for sourcing biopharmaceutical investment opportunities worldwide. In 2003 he became Chairman & CEO of Cyprotex PLC in the UK, a specialist provider of technology and information to evaluate and optimize the ADME, toxicity and pharmacokinetic properties of potential drugs from early discovery projects through to IND submissions, a position he held until 2008.

He joined Rosecastle as an adviser in 2009.

Robert holds a BA from the University of Massachusetts Amherst.